IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM
Authors:
- David HallifaxDHDavid Hallifax
- R. Scott ObachROR. Scott Obach
- J. Brian HoustonJHJ. Brian Houston
Open Access
- 2 March 2005
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (6) , 837-844
Abstract
The success of in vitro derived Ki values for predicting drug-drug interactions in vivo has been mixed. For example, the use of hepatic input concentration of inhibitor has resolved the negative and positive interactions on the qualitative level, eliminating false negative predictions. However, several examples of false positives and a high incidence of over-predictions of true positive interactions indicated a need for incorporation of additional factors. The aim of this study was to investigate the effect of parallel elimination pathways as a possible reason for false positives and over-predictions. Simulation studies indicated that the degree of interaction (assessed by area under the plasma concentration-time curve ratio in the presence and absence of inhibitor) depends largely on the fraction of substrate metabolized by the particular P450 enzyme (fmCYPi) that is inhibited. The current analysis focused on CYP2D6 interactions due to the well documented genetic polymorphism and the ability to estimate fmCYP2D6 readily from in vivo data obtained in extensive and poor metabolizers. Based on either a phenotype study or an alternative regression analysis approach, the fmCYP2D6 values of 0.37 to 0.94 and 0.25 to 0.89, respectively, were obtained for nine substrates. Prediction of 44 drug-drug interaction studies was improved by the combination of parallel pathways of elimination and their susceptibility to inhibition. The overall success of predicting positive and negative interactions was increased from 54% to 84%, and the number of over-predictions was substantially reduced. It is concluded that incorporating parallel pathways provides a valuable step forward in making quantitative predictions of drug-drug interactions from in vitro data.Keywords
This publication has 27 references indexed in Scilit:
- Inhibition‐Based Metabolic Drug–Drug Interactions: Predictions from In Vitro DataJournal of Pharmaceutical Sciences, 2002
- Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450sDrug Metabolism and Disposition, 2000
- Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the LiverPharmaceutical Research, 2000
- Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the LiverPharmacological Reviews, 1998
- Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine*Clinical Pharmacology & Therapeutics, 1998
- Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.The Journal of Pharmacology and Experimental Therapeutics, 1994
- Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.The Journal of Pharmacology and Experimental Therapeutics, 1991
- Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.The Journal of Pharmacology and Experimental Therapeutics, 1989
- Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profilesJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Polymorphic metabolism of metoprolol: Clinical studiesEuropean Journal of Clinical Pharmacology, 1985